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Introduction
The recent successes of genome-wide association studies 
and  the  promises  of  whole  genome  sequencing  fuel 
interest  in  the  translation  of  this  new  wave  of  basic 
genetic  knowledge  to  health  care  practice.  Knowledge 
about  genetic  risk  factors  may  be  used  to  target 
diagnostic, preventive, and therapeutic interventions for 
com  plex disorders based on a person’s genetic risk, or to 
complement existing risk models based on classical non-
genetic factors, such as the Framingham risk score for 
cardiovascular  disease.  Implementation  of  genetic  risk 
prediction in health care requires a series of studies that 
encompass  all  phases  of  translational  research  [1,2], 
starting with a comprehensive evaluation of genetic risk 
prediction.
With  increasing  numbers  of  discovered  genetic 
markers that can be used in future genetic risk prediction 
studies,  it  is  crucial  to  enhance  the  quality  of  the 
reporting  of  these  studies,  since  valid  interpretation 
could be compromised by the lack of reporting of key 
information. Information that is often missing includes 
details in the description of how the study was designed 
and conducted (for example, how genetic variants were 
selected  and  coded,  how  risk  models  or  genetic  risk 
scores were constructed, and how risk categories were 
chosen),  or  how  the  results  should  be  interpreted.  An 
appropriate  assessment  of  the  study’s  strengths  and 
weak  nesses  is  not  possible  without  this  information. 
There is ample evidence that prediction research often 
suffers from poor design and bias, and these may also 
have  an  impact  on  the  results  of  the  studies  and  on 
models of disease outcomes based on these studies [3-5]. 
Although  most  prognostic  studies  published  to  date 
claim  significant  results  [6,7],  very  few  translate  to 
clinically  useful  applications.  Just  as  for  observational 
epidemiological studies [8], poor reporting complicates 
the  use  of  the  specific  study  for  research,  clinical,  or 
public  health  purposes  and  hampers  the  synthesis  of 
evidence across studies.
Reporting guidelines have been published for various 
research designs [9], and these contain many items that 
are  also  relevant  to  genetic  risk  prediction  studies.  In 
particular, the guidelines for genetic association studies 
(STrenghtening  the  REporting  of  Genetic  Association 
studies - STREGA) have relevant items on the assessment 
of genetic variants, and the guidelines for observational 
studies  (Strengthening  the  Reporting  of  OBservational 
studies in Epidemiology - STROBE) have relevant items 
about the reporting of study design. The guidelines for 
diagnostic studies (STAndards for Reporting Diagnostic 
accuracy - STARD) and those for tumor marker prog-
nostic  studies  (Reporting  of  tumor  MARKer  studies  - 
REMARK) include relevant items about test evaluation; 
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risk prediction [10-13]. However, none of these guidelines 
are  fully  suited  to  genetic  risk  prediction  studies,  an 
emerging  field  of  investigation  with  specific  methodo-
logical  issues  that  need  to  be  addressed,  such  as  the 
handling of large numbers of genetic variants (from tens 
to  tens  of  thousands)  and  flexibility  in  handling  such 
large  numbers  in  analyses.  We  organized  a  two-day 
workshop with an international group of risk prediction 
researchers, epidemiologists, geneticists, methodologists, 
statisticians,  and  journal  editors  to  develop  recom-
mendations for the reporting of genetic risk prediction 
studies - the GRIPS statement.
Genetic	risk	prediction	studies
Genetic  risk  prediction  studies  typically  develop  or 
validate models that predict the risk of disease, but they 
are also being investigated for use in predicting prog  nostic 
outcome, treatment response, or treatment-related harms. 
Risk  prediction  models  are  statistical  algorithms,  which 
may be simple genetic risk scores (for example, risk allele 
counts), may be based on regression analyses (for example, 
weighted risk scores or predicted risks), or may be based 
on  more  complex  analytic  approaches,  such  as  support 
vector machine learning or classification trees. The risk 
models may be based on genetic variants only, or include 
both genetic and non-genetic risk factors [14].
Aims	and	use	of	the	GRIPS	statement
The  25  items  of  the  GRIPS  statement  are  intended  to 
maximize the transparency, quality, and completeness of 
reporting  on  research  methodology  and  findings  in  a 
particular study. It is important to emphasize that these 
recommendations are guidelines only for how to report 
research and do not prescribe how to perform genetic 
risk prediction studies. The guidelines do not support or 
oppose  the  choice  of  any  particular  study  design  or 
method; for example, the guidelines recommend that the 
study population should be described, but do not specify 
which population is preferred in a particular study.
The  intended  audience  for  the  reporting  guidelines  is 
broad  and  includes  epidemiologists,  geneticists,  statis-
ticians, clinician scientists, and laboratory-based investi-
gators who undertake genetic risk prediction studies, as 
well as journal editors and reviewers who have to appraise 
the  design,  conduct  and  analysis  of  such  studies.  In 
addition, it includes ‘users’ of such studies who wish to 
understand the basic premise, design, and limitations of 
genetic prediction studies in order to interpret the results 
for  their  potential  application  in  health  care.  These 
guidelines are also intended to ensure that essential data 
from future genetic risk prediction studies are presented in 
standardized  form,  which  will  facilitate  information 
synthesis as part of systematic reviews and meta-analyses.
Items presented in the checklist are relevant for a wide 
array of risk prediction studies, because GRIPS focuses 
on the main aspects of the design and analysis of risk 
prediction studies. GRIPS does not address randomized 
trials that may be performed to test risk models, nor does 
it specifically address decision analyses, cost-effectiveness 
analyses, assessment of health care needs, or assessment 
of barriers to health care implementation [15]. Once the 
performance of a risk model has been established, these 
next  steps  toward  implementation  require  further 
evaluation  [10,16].  For  the  reporting  of  these  studies, 
which go beyond the assessment of genetic risk models 
as such, additional requirements apply. However, proper 
documentation of genetic predictive research according 
to  GRIPS  might  facilitate  the  translation  of  research 
findings into clinical and public health practice.
Development	of	the	GRIPS	statement
The GRIPS statement was developed by a multidiscipli-
nary panel of 25 risk prediction researchers, epidemio-
logists,  geneticists,  methodologists,  statisticians,  and 
journal  editors,  seven  of  whom  were  also  part  of  the 
STREGA initiative [11]. They attended a two-day meeting 
in  Atlanta,  Georgia  (US)  in  December  2009  that  was 
sponsored  by  the  US  Centers  for  Disease  Control  and 
Prevention on behalf of the Human Genome Epidemio-
logy Network (HuGENet) [17]. Participants discussed a 
draft  version  of  the  guidelines  that  was  prepared  and 
distributed  before  the  meeting.  This  draft  version  was 
developed on the basis of existing reporting guidelines, 
namely STREGA [11], REMARK [13], and STARD [12]. 
These were selected out of all available guidelines [18] 
because of their focus on observational study designs and 
genetic factors (STREGA), prediction models (REMARK), 
and test evaluation (REMARK and STARD). During the 
meeting, methodological issues pertinent to risk predic-
tion studies were addressed in presentations. Workshop 
participants  were  asked  to  change,  combine,  or  delete 
proposed  items  and  add  additional  items  if  necessary. 
Participants had extensive post-meeting electronic corres-
pondence.  To  harmonize  our  recommendations  for 
genetic risk prediction studies with previous guidelines, 
we  chose  the  same  wording  for  the  items  wherever 
possible.  Finally,  we  tried  to  create  consistency  with 
previous guidelines for the evaluation of risk prediction 
studies of cardiovascular diseases and cancer [2,19]. The 
final version of the checklist is presented in Table 1.
The	GRIPS	explanation	and	elaboration	article
Accompanying  this  GRIPS  statement,  an  Explanation 
and  Elaboration  document  has  been  written  [20], 
modeled  after  those  developed  for  other  reporting 
guidelines [21-24]. The Explanation and Elaboration docu-
ment  illustrates  each  item  with  at  least  one  published 
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Page 2 of 5Table	1.	Reporting	recommendations	for	evaluation	of	risk	prediction	models	that	include	genetic	variants
Title and abstract  1  (a) Identify the article as a study of risk prediction using genetic factors. (b) Use recommended keywords in the 
      abstract: genetic or genomic, risk, prediction
   
Introduction   
  Background and rationale  2  Explain the scientific background and rationale for the prediction study
  Objectives  3  Specify the study objectives and state the specific model(s) that is/are investigated. State if the study concerns  
      the development of the model(s), a validation effort, or both
   
Methods   
  Study design and setting  4*  Specify the key elements of the study design and describe the setting, locations, and relevant dates, including  
      periods of recruitment, follow-up, and data collection
  Participants  5*  Describe eligibility criteria for participants, and sources and methods of selection of participants
  Variables: definition  6*  Clearly define all participant characteristics, risk factors and outcomes. Clearly define genetic variants using a  
      widely used nomenclature system
  Variables: assessment  7*  (a) Describe sources of data and details of methods of assessment (measurement) for each variable. (b) Give a  
      detailed description of genotyping and other laboratory methods
  Variables: coding  8  (a) Describe how genetic variants were handled in the analyses. (b) Explain how other quantitative variables were   
      handled in the analyses. If applicable, describe which groupings were chosen, and why
  Analysis: risk model  9  Specify the procedure and data used for the derivation of the risk model. Specify which candidate variables  
  construction    were initially examined or considered for inclusion in models. Include details of any variable selection procedures   
      and other model-building issues. Specify the horizon of risk prediction (for example, 5-year risk)
  Analysis: validation  10  Specify the procedure and data used for the validation of the risk model
  Analysis: missing data  11  Specify how missing data were handled
  Analysis: statistical methods  12  Specify all measures used for the evaluation of the risk model, including, but not limited to, measures of model fit   
      and predictive ability
  Analysis: other  13  Describe all subgroups, interactions, and exploratory analyses that were examined
   
Results   
  Participants  14*  Report the numbers of individuals at each stage of the study. Give reasons for non-participation at each stage.  
      Report the number of participants not genotyped, and reasons why they were not genotyped
  Descriptives: population  15*  Report demographic and clinical characteristics of the study population, including risk factors used in the risk  
      modeling
  Descriptives: model estimates  16  Report unadjusted associations between the variables in the risk model(s) and the outcome. Report adjusted  
      estimates and their precision from the full risk model(s) for each variable
  Risk distributions  17*  Report distributions of predicted risks and/or risk scores
  Assessment  18  Report measures of model fit and predictive ability, and any other performance measures, if pertinent
  Validation  19  Report any validation of the risk model(s)
  Other analyses   20  Present results of any subgroup, interaction, or exploratory analyses, whenever pertinent
   
Discussion   
  Limitations  21  Discuss limitations and assumptions of the study, particularly those concerning study design, selection of  
      participants, and measurements and analyses, and discuss their impact on the results of the study
  Interpretation  22  Give an overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from  
      similar studies, and other relevant evidence
  Generalizability  23  Discuss the generalizability and, if pertinent, the health care relevance of the study results
   
Other
  Supplementary information  24  State whether databases for the analyzed data, risk models, and/or protocols are or will become publicly  
      available and, if so, how they can be accessed
  Funding  25  Give the source of funding and the role of the funders for the present study. State whether there are any conflicts   
      of interest
Items marked with an asterisk should be reported for every population in the study.
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explains the rationale for its inclusion in the checklist, 
and  presents  details  of  the  items  that  need  to  be 
addressed to ensure transparent reporting. The Expla  na-
tion and Elaboration document was produced after the 
meeting.  The  document  was  prepared  by  a  small 
subgroup and shared with all workshop participants for 
additional revisions and final approval.
Conclusions	and	future	directions
High-quality reporting reveals the strengths and weak-
nesses of empirical studies, facilitates the interpretation 
of the scientific and health care relevance of the results - 
especially  within  the  framework  of  systematic  reviews 
and meta-analyses - and helps build a solid evidence base 
for  moving  genomic  discoveries  into  applications  in 
health care practice. The GRIPS guidelines were developed 
to improve the transparency, quality and completeness of 
the  reporting  of  genetic  risk  prediction  studies.  As 
outlined in the introduction, GRIPS does not prescribe 
how studies should be designed, conducted, or analyzed, 
and therefore the guidelines should not be used to assess 
the  quality  of  empirical  studies  [25].  The  guidelines 
should be used only to check whether all essential items 
are adequately reported.
Finally,  the  methodology  for  designing  and  assessing 
genetic  risk  prediction  models  is  still  developing.  For 
example,  newer  measures  of  reclassification  were  first 
intro  duced in 2007 [26], and several alternative reclassi  fi-
ca  tion  measures  have  been  proposed  [27].  Which 
measures  to  apply  and  when  to  use  measures  of  re-
classification are still subject to ongoing evaluation and 
discussion  [28].  Furthermore,  alternative  strategies  for 
constructing  risk  models  other  than  simple  regression 
analyses are being explored, and these may add increased 
complexity to the reporting. In formulating the items of 
the  GRIPS  statement,  these  methodological  advances 
were  anticipated.  It  is  for  this  reason  that  the  GRIPS 
statement recommends how a study should be reported 
and not how a study should be conducted or analyzed. 
Therefore, methodological and analytical developments 
will not immediately impact the validity and relevance of 
the items, but the GRIPS statement will be updated when 
this is warranted by essential new developments in the 
construction and evaluation of genetic risk models.
Co-publication
In order to encourage dissemination of the GRIPS state-
ment, this article will also be published by PLoS Medicine, 
Annals of Internal Medicine, BMJ, Circulation: Cardio­
vascular Genetics, European Journal of Clinical Investiga­
tion, European Journal of Epidemiology, European Journal 
of  Human  Genetics,  Genetics  in  Medicine,  Genome 
Medicine, and Journal of Clinical Epidemiology.
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